用于治疗状细胞病的眼器
1Internal Medicine, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.
Expert opinion on pharmacotherapy
|April 3, 2025
概括
一种新的状细胞疾病治疗方法Osivelotor增加了血红蛋白,并减少了细胞状. 然而,它的有效性可能是有限的,类似于voxelotor,在批准之前需要进一步的研究.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 遗传性血液疾病 遗传性血液疾病
背景情况:
- 状细胞疾病 (SCD) 涉及异常的状血红蛋白 (HbS) 聚合,导致预期寿命缩短.
- 增加红细胞 (红细胞) 中的氧化HbS是一种抑制HbS聚合和并发症的策略.
- 对于SCD治疗,正在研究新的氧 afinity调节器.
研究的目的:
- 审查振器的特征和初步结果,这是SCD的新型氧亲和度调节器.
- 为了比较osivelotor的药物动力学特性与voxelotor.
- 评估osivelotor在SCD中改善临床结果的潜力.
主要方法:
- 对SCD患者使用osivelotor的临床试验数据的综述.
- 对药物动力学特性和剂量反应关系的分析.
- 对血红蛋白水平,红细胞计数和红细胞形的影响的评估.
主要成果:
- 奥西维洛托显示出血红蛋白水平和红细胞计数的增加.
- 观察到,随着 osivelotor 治疗,红细胞形的减少.
- 据报道,在早期试验中,该药物被耐受性良好.
结论:
- 奥西维洛托与声声器共享一种机制,尽管Hb水平上升,但对疗效提出了疑问.
- 需要进一步的研究来解决局限性并确定 osivelotor 的治疗价值.
- 在治疗状细胞病的潜在药物批准之前,Osivelotor需要进行额外的研究.
更多相关视频
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
1.7K
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
19.3K
相关概念视频
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
131
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
131
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
103
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
103
01:27Disorders of Erythrocytes
823
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
823
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
124
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
124
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
110
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
110
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K